查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615463

格雷夫茲病市場：按診斷、治療、給藥途徑、分銷管道和最終用戶分類 - 全球預測 2025-2030

Graves Disease Market by Diagnosis (Blood Tests, Imaging Tests, Physical Examination), Treatment (Adjunctive Treatments, Medications, Radioactive Iodine Therapy), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年格雷夫茲病市場價值為5.8385億美元，預計到2024年將達到6.1351億美元，複合年成長率為5.42%，到2030年將達到8.4489億美元。

格雷夫茲病市場範圍和定義涵蓋了對這種以甲狀腺激素過量產生為特徵的自體免疫疾病的全面分析。這種需求源於其普遍存在以及對有效的診斷和治療方法來管理甲狀腺功能亢進、眼科疾病和皮膚病等疾病的需求。最終用途主要包括醫院、診所和研究機構。推動市場成長的主要影響因素包括發病率增加、先進的診斷能力以及對自體免疫疾病的日益關注。其中蘊藏豐富的商機，包括生物製藥、免疫療法等新型治療劑的開發，以及利用人工智慧進行早期診斷等。對個人化醫療和以患者為中心的護理模式的投資有可能顯著推動成長，特別是在醫療保健成本增加的情況下。然而，其局限性仍然存在，例如治療費用高、現有藥物的副作用以及自體免疫疾病的複雜性，這些可能會阻礙其廣泛使用。此外，監管障礙和需要大規模臨床試驗來證明有效性和安全性等挑戰仍然是重大問題。為了加強對格雷夫茲病的認知和治療，我們需要專注於分子層次的研究，探索遺傳傾向和環境觸發因素。市場參與企業應優先考慮與研究機構合作，以推動新製劑和診斷工具的研發。在醫療政策變化和技術進步的支持下，格雷夫茲病市場持續緩慢但穩定的成長。公司需要緊跟監管變化，並努力透過生物相似藥等創新來降低治療成本。策略夥伴關係、產品多元化和進入新興國家市場可以增加市場潛力。此外，我們以患者為中心的方法和治療方案教育可以透過提高患者的依從性和結果、提高品牌信任和忠誠度來幫助建立市場領導地位。

主要市場統計
基準年[2023] 5.8385億美元
預計年份 [2024] 61351萬美元
預測年份 [2030] 84489萬美元
複合年成長率（%） 5.42%

市場動態：針對快速發展的格雷夫茲病市場揭示的關鍵市場洞察

供需的動態交互作用正在改變格雷夫茲病市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球自體免疫疾病盛行率上升
    • 在政府主導提高公眾意識
    • 個人化醫療需求不斷成長
  • 市場限制因素
    • 與先進治療方法和診斷相關的高成本
  • 市場機會
    • 活性化先進治療藥物的研發活動
    • 建立研究機構與生技公司之間的合作關係
  • 市場挑戰
    • 法規環境嚴峻、核准程序複雜

波特的五力：駕馭格雷夫茲病市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解格雷夫茲病市場的外部影響

外部宏觀環境因素在塑造格雷夫茲病市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解格雷夫茲病市場的競爭狀況

格雷夫茲病市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣格雷夫茲病市場供應商的績效評估

FPNV定位矩陣是評估格雷夫茲病市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了格雷夫茲病市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，格雷夫茲病市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球自體免疫疾病的盛行率上升
      • 隨著政府措施的增加，公眾意識也在增強
      • 個人化醫療需求不斷成長
    • 抑制因素
      • 與先進治療和診斷相關的高成本
    • 機會
      • 持續進行先進治療方法的研究和開發活動
      • 研究機構與生技公司之間的新合作
    • 任務
      • 法規環境嚴格、核准程序複雜
  • 市場區隔分析
    • 治療：放射性碘療法在格雷夫茲病治療的普及
    • 給藥途徑：靜脈注射擴大用於格雷夫茲病的急性治療
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 格雷夫茲病診斷市場

  • 驗血
    • 免費 T4 和 T3 級別
    • 甲狀腺刺激素(TSH) 水平
    • TSH 受體抗體 (TSH-RAb)
  • 影像檢查
    • CT 或 MRI 掃描
    • 攝入放射性碘
    • 甲狀腺超音波檢查
  • 體檢

第7章格雷夫茲病市場的治療

  • 輔助治療
  • 藥品
    • 抗甲狀腺藥物
    • BETA受體阻斷劑
      • 阿替洛爾
      • Propranolol
  • 放射性碘治療
  • 外科手術

第8章格雷夫茲病市場：依給藥途徑

  • 靜脈
  • 口服
  • 手術介入

第9章格雷夫茲病市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專業藥房

第 10 章 格雷夫茲病市場：依最終用戶分類

  • 醫療服務提供方
  • 醫院/診所
  • 個別患者

第11章 美洲格雷夫茲病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區格雷夫茲病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲格雷夫茲病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • IBSA USA 續簽了與高爾夫球手 Azahara Muñoz 的合作關係，以提高 Tirosint-SOL 的知名度，Tirosint-SOL 是一種經 FDA核准的甲狀腺機能低下症治療藥物，具有無與倫比的靈活性和便利性。
    • 信達生物抗IGF-1R抗體IBI311在中國獲得甲狀腺眼疾的優先審評，支持重大臨床進展與全球擴張
    • 隨著歐盟核准甲狀腺眼疾治療 teprotumumab，安進開始在格雷夫茲病治療方面取得進展，並計劃長期市場擴張和加強患者照護
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • AdvanceCor GmbH
  • Amgen Inc.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Immunovant, Inc.
  • Jubilant Pharma Holdings Inc.
  • Lannett Company, Inc.
  • Lupin Limited
  • Medtronic PLC
  • Merck KGaA
  • Novartis AG
  • Omeros Corp
  • OSE Immunotherapeutics SA
  • Protheragen Inc
  • RLC Labs, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.
  • Zenas BioPharma, Inc.
Product Code: MRR-42653751EADD

The Graves Disease Market was valued at USD 583.85 million in 2023, expected to reach USD 613.51 million in 2024, and is projected to grow at a CAGR of 5.42%, to USD 844.89 million by 2030.

The scope and definition of the Graves' Disease market encompass a comprehensive analysis of this autoimmune disorder characterized by overproduction of thyroid hormones. The necessity stems from its prevalence and the need for effective diagnostics and therapeutics to manage symptoms like hyperthyroidism, eye diseases, and skin conditions. The application involves pharmaceuticals, diagnostics, and personalized medicine, while the end-use scope primarily includes hospitals, clinics, and research institutes. Key influencing factors driving market growth include increasing incidence rates, advanced diagnostic capabilities, and a growing focus on autoimmune diseases. Opportunities abound in developing novel therapeutics, such as biologics and immunotherapies, and leveraging AI for early diagnosis. Investing in personalized medicine and patient-centric care models can significantly drive growth, especially with rising healthcare spending. However, limitations persist, like the high cost of treatment, side effects of current medications, and the complexity of autoimmune conditions, potentially hindering widespread adoption. Moreover, challenges such as regulatory hurdles and the need for extensive clinical trials to prove efficacy and safety remain pivotal issues. Innovation should focus on molecular-level research, exploring genetic predispositions and environmental triggers to enhance understanding and treatment of Graves' Disease. Market participants should prioritize collaborations with research institutions to drive R&D in novel drug formulations and diagnostic tools. The nature of the market leans towards moderate but consistent growth, tethered by healthcare policy changes and technological advancements. Companies should stay abreast of regulatory shifts and work towards reducing treatment costs through innovations like biosimilars. Strategic partnerships, product diversification, and market entry in emerging economies could ramp up market potential. Additionally, a patient-focused approach and education about treatment options could foster better patient adherence and outcomes, establishing market leaders through enhanced brand trust and loyalty.

KEY MARKET STATISTICS
Base Year [2023] USD 583.85 million
Estimated Year [2024] USD 613.51 million
Forecast Year [2030] USD 844.89 million
CAGR (%) 5.42%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Graves Disease Market

The Graves Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of autoimmune disorders globally
    • Increasing awareness among population with rising government initiatives
    • Growing demand for personalized medecine
  • Market Restraints
    • High cost associated with advanced therapeutics and diagnostics
  • Market Opportunities
    • Ongoing research and development activities for advanced therapies
    • Emerging collaboration between research institutes and biotech firms
  • Market Challenges
    • Stringent regulatory environments and complex approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Graves Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Graves Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Graves Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Graves Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Graves Disease Market

A detailed market share analysis in the Graves Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Graves Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Graves Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Graves Disease Market

A strategic analysis of the Graves Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Graves Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AdvanceCor GmbH, Amgen Inc., Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GSK plc, Immunovant, Inc., Jubilant Pharma Holdings Inc., Lannett Company, Inc., Lupin Limited, Medtronic PLC, Merck KGaA, Novartis AG, Omeros Corp, OSE Immunotherapeutics SA, Protheragen Inc, RLC Labs, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Viatris Inc., and Zenas BioPharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Graves Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnosis, market is studied across Blood Tests, Imaging Tests, and Physical Examination. The Blood Tests is further studied across Free T4 & T3 Levels, Thyroid-Stimulating Hormone (TSH) Levels, and TSH Receptor Antibodies (TSH-RAb). The Imaging Tests is further studied across CT or MRI Scans, Radioactive Iodine Uptake, and Thyroid Ultrasound.
  • Based on Treatment, market is studied across Adjunctive Treatments, Medications, Radioactive Iodine Therapy, and Surgery. The Medications is further studied across Anti-thyroid Drugs and Beta-Blockers. The Beta-Blockers is further studied across Atenolol and Propranolol.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Surgical Intervention.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies.
  • Based on End User, market is studied across Healthcare Providers, Hospitals & Clinics, and Individual Patients.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of autoimmune disorders globally
      • 5.1.1.2. Increasing awareness among population with rising government initiatives
      • 5.1.1.3. Growing demand for personalized medecine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced therapeutics and diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development activities for advanced therapies
      • 5.1.3.2. Emerging collaboration between research institutes and biotech firms
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environments and complex approval procedures
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Proliferation of radioactive iodine therapy for Graves' disease treatment
    • 5.2.2. Route of Administration: Growing application of intravenous administration for acute management of Graves' disease
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Graves Disease Market, by Diagnosis

  • 6.1. Introduction
  • 6.2. Blood Tests
    • 6.2.1. Free T4 & T3 Levels
    • 6.2.2. Thyroid-Stimulating Hormone (TSH) Levels
    • 6.2.3. TSH Receptor Antibodies (TSH-RAb)
  • 6.3. Imaging Tests
    • 6.3.1. CT or MRI Scans
    • 6.3.2. Radioactive Iodine Uptake
    • 6.3.3. Thyroid Ultrasound
  • 6.4. Physical Examination

7. Graves Disease Market, by Treatment

  • 7.1. Introduction
  • 7.2. Adjunctive Treatments
  • 7.3. Medications
    • 7.3.1. Anti-thyroid Drugs
    • 7.3.2. Beta-Blockers
      • 7.3.2.1. Atenolol
      • 7.3.2.2. Propranolol
  • 7.4. Radioactive Iodine Therapy
  • 7.5. Surgery

8. Graves Disease Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Surgical Intervention

9. Graves Disease Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies
  • 9.5. Specialty Pharmacies

10. Graves Disease Market, by End User

  • 10.1. Introduction
  • 10.2. Healthcare Providers
  • 10.3. Hospitals & Clinics
  • 10.4. Individual Patients

11. Americas Graves Disease Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Graves Disease Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Graves Disease Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. IBSA USA Renews Alliance with Golfer Azahara Munoz to Boost Awareness for FDA-Approved Tirosint-SOL, the Hypothyroidism Treatment Offering Unmatched Flexibility and Convenience
    • 14.3.2. Innovent Biologics' Advancement Anti-IGF-1R Antibody IBI311 Secures Priority Review for Thyroid Eye Disease in China, Supporting Major Clinical Advances and Global Expansion
    • 14.3.3. Amgen Moves to Advance Graves' Disease Treatment with EU Approval of Teprotumumab for Thyroid Eye Disease; Plans for Long-Term Market Expansion and Patient Care Enhancements
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AdvanceCor GmbH
  • 4. Amgen Inc.
  • 5. Bayer AG
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. GSK plc
  • 9. Immunovant, Inc.
  • 10. Jubilant Pharma Holdings Inc.
  • 11. Lannett Company, Inc.
  • 12. Lupin Limited
  • 13. Medtronic PLC
  • 14. Merck KGaA
  • 15. Novartis AG
  • 16. Omeros Corp
  • 17. OSE Immunotherapeutics SA
  • 18. Protheragen Inc
  • 19. RLC Labs, Inc.
  • 20. Sanofi S.A.
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. Thermo Fisher Scientific Inc.
  • 23. Viatris Inc.
  • 24. Zenas BioPharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GRAVES DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. GRAVES DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GRAVES DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GRAVES DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY CT OR MRI SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADJUNCTIVE TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTI-THYROID DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPRANOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GRAVES DISEASE MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL GRAVES DISEASE MARKET SIZE, BY INDIVIDUAL PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 341. RUSSIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 342. RUSSIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 343. RUSSIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 349. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 350. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 351. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 352. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 358. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 359. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 360. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 361. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 362. SPAIN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 363. SPAIN